DocWire News recently talked to Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, Inc., a company developing innovative therapies that target various phases of cell control for treating advanced cancers, among other serious diseases. Mr. Rombotis discussed the strides his company is making in developing and testing targeted therapies that may actually drive cancer cells “to commit suicide.” […]

Manufacturing issues are common with regenerative medicines. And so it goes for PolarityTE’s investigational new drug submission for SkinTE. On Tuesday the Salt Lake Salt Lake City biotech revealed that it has put its investigational new drug (IND) application on hold in chronic cutaneous ulcers to address chemistry, manufacturing and control (CMC) issues raised by the agency. The […]

Shoreline Biosciences, an immunotherapy company formed in 2020 during the early days of the COVID-19 pandemic, was propelled into the proverbial catbird’s seat this summer with two mega-deals, and now plans to double its employee base from 50 to 100 in the coming six to nine months. Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic […]